Belkouch Ahmed, Jidane Said, Chouaib Naoufal, Elbouti Anass, Nebhani Tahir, Sirbou Rachid, Bakkali Hicham, Belyamani Lahcen
Emergency Department, Mohamed V Military Hospital of Instruction, Faculty of Medicine and Pharmacy, Rabat, Morocco.
Pan Afr Med J. 2015 May 19;21:37. doi: 10.11604/pamj.2015.21.37.6491. eCollection 2015.
Thrombolysis has radically changed the prognosis of acute ischemic stroke. Tenecteplase is a modified form of rt-PA with greater specificity for fibrin and a longer half-life. We report the experience of a Moroccan tertiary hospital in thrombolysis using Tenecteplase.
We conducted an open prospective study of all patients who were treated with Tenecteplase for an acute ischemic stroke admitted to our emergency department. Tenecteplase was administered intravenously at a dose of 0.4 mg/kg single bolus. The primary outcome measure was the proportion of patients achieving significant early neurological recovery defined as an improvement of 4 or more points on the NIHSS score at 24h.
13 patients had been treated by intravenous thrombolysis. 31% were women. Mean age was 63 years old. The mean NIHSS score at admission was 14.3 and 24h after was at 9.1. The right middle cerebral artery was involved in 69% of cases. The carotid atherosclerosis was predominant 63.3% and the cardio embolic etiology 27%. The mean time to the first medical contact after the onset of symptoms was 3h 30 min. One patient presented a capsulo-lenticular hematoma of 5 mm(3) in the same side of the ischemic stroke.
Tenecteplase is a more interesting thrombolytic than alteplase, it seems to be more suitable for thrombolysis in our center.
溶栓治疗已从根本上改变了急性缺血性卒中的预后。替奈普酶是重组组织型纤溶酶原激活剂(rt-PA)的一种改良形式,对纤维蛋白具有更高的特异性和更长的半衰期。我们报告了一家摩洛哥三级医院使用替奈普酶进行溶栓治疗的经验。
我们对在急诊科接受替奈普酶治疗急性缺血性卒中的所有患者进行了一项开放性前瞻性研究。替奈普酶以0.4mg/kg单次静脉推注给药。主要结局指标是在24小时时美国国立卫生研究院卒中量表(NIHSS)评分改善4分或更多分定义为实现显著早期神经功能恢复的患者比例。
13例患者接受了静脉溶栓治疗。31%为女性。平均年龄为63岁。入院时平均NIHSS评分为14.3,24小时后为9.1。69%的病例累及右侧大脑中动脉。颈动脉粥样硬化占主导地位,为63.3%,心源性栓塞病因占27%。症状发作后至首次医疗接触的平均时间为3小时30分钟。1例患者在缺血性卒中同侧出现了5mm³的豆状核血肿。
替奈普酶是一种比阿替普酶更具优势的溶栓剂,在我们中心似乎更适合用于溶栓治疗。